Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of
systemic inflammation.
Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful
anti-inflammatory effects.
In this study we plan to determine the effects of Doxycycline in patients with stable heart
failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and
ventilator efficiency measured with a cardiopulmonary test.